Satraplatin is primarily utilized in the field of oncology as an anticancer agent. It is a platinum-based compound designed to treat various types of cancer, particularly prostate cancer. Its mechanism of action involves the inhibition of DNA replication in cancer cells, leading to cell death. Satraplatin is often considered for patients who have not responded to other forms of chemotherapy or who are unable to tolerate more aggressive treatments. It is administered orally, which offers a convenient alternative to intravenous chemotherapy, reducing the need for hospital visits and improving patient compliance. Clinical trials have explored its efficacy in combination with other anticancer drugs to enhance therapeutic outcomes. Additionally, its potential to overcome resistance to other platinum-based drugs makes it a valuable option in certain cancer treatment protocols.